Dr. Myrna L Lopez, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 65 Ave Barbosa, Arecibo Medical Plaza, Suite 102, Arecibo, PR 00612 Phone: 787-879-4811 Fax: 787-879-4811 |
Dr. Jinetsy Ines Rivera-ortiz, Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: Metropolitan Office Building, Num 5 Calle Palma, Arecibo, PR 00612 Phone: 787-650-1071 Fax: 787-650-1056 |
Maria Del Carmen Marrero Mendez, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 11 Calle Ana Lens De Susoni, Arecibo, PR 00612 Phone: 787-568-3573 |
News Archive
Today, the South East Trust in Northern Ireland, comprising five hospitals, is live with Sectra RIS/PACS. These are the first of 25 hospitals, together performing more than 1 million examinations per year, that will be connected in one common radiology IT solution called NIPACS.
Cardiologists and pulmonologists at Rush University Medical Center have teamed up to provide a new and better approach to treating patients with pulmonary hypertension, a disease affecting the heart and lungs. The new Rush Pulmonary Hypertension Clinic brings together a multidisciplinary team of clinicians with specialized training to care for patients with this very complex disease.
Alcoholism and smoking have a high rate of co-occurrence in the general population. Yet little is known about the co-morbidity of alcoholism and smoking among American Indians.
BIO-key International, Inc., a leader in finger-based biometric identification solutions announced the award of another contract for a fingerprint biometric identity solution built on the fusion of BIO-key and MorphoTrak algorithms. The first contract for this fused solution, awarded to MorphoTrak (a Morpho company) by Lockheed Martin in September 2009, provides fingerprint identification technology for the FBI's Next Generation Identification (NGI) system. This new contract will provide large scale advanced finger matching technology to an overseas customer.
Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.
› Verified 9 days ago